Quantitative systems pharmacology

From Wikipedia, the free encyclopedia

Quantitative systems pharmacology (QSP) is a discipline within biomedical research that uses mathematical computer models to characterize biological systems, disease processes and drug pharmacology.[1][2] QSP can be viewed as a sub-discipline of pharmacometrics that focuses on modeling the mechanisms of drug pharmacokinetics (PK), pharmacodynamics (PD), and disease processes using a systems pharmacology point of view. QSP models are typically defined by systems of ordinary differential equations (ODE) that depict the dynamical properties of the interaction between the drug and the biological system.

QSP can be used to generate biological/pharmacological hypotheses in silico to aid in the design of in vitro or in vivo non-clinical and clinical experiments. This can help to guide biomedical experiments so that they yield more meaningful data. QSP is increasingly being used for this purpose in pharmaceutical research & development to help guide the discovery and development of new therapies.[3][4] QSP has been used by the FDA in a clinical pharmacology review.[5]

Origin[edit]

QSP emerged as a discipline through two workshops held at the National Institutes of Health (NIH) in 2008 and 2010, with the goal of merging of systems biology and pharmacology. The workshops outlined a need for a mathematical discipline to aid in translational medicine. QSP proposed integrating concepts, methods, and investigators from computational biology, systems biology, and biological engineering into pharmacology. [2]

A review of the history and future of QSP identified areas where it has advanced understanding of drug mechanisms, supported preclinical to clinical translation, and in general aided in drug development. The FDA has included QSP as a component of the Model-Informed Drug Development Program. [6] [7]

References[edit]

  1. ^ Geerts, Hugo; Spiros, Athan; Roberts, Patrick; Carr, Robert (2013-06-01). "Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development". Journal of Pharmacokinetics and Pharmacodynamics. 40 (3): 257–265. doi:10.1007/s10928-013-9297-1. ISSN 1573-8744. PMID 23338980. S2CID 1588528.
  2. ^ a b Ward, Rebecca. "Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms" (PDF). www.nigms.nih.gov. NIH. Retrieved 17 July 2023.
  3. ^ Leil, Tarek A.; Bertz, Richard (2014-01-01). "Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development". Frontiers in Pharmacology. 5: 247. doi:10.3389/fphar.2014.00247. PMC 4226160. PMID 25426074.
  4. ^ Russell, John. "What is (Quantitative) Systems Pharmacology?". www.bio-itworld.com. Bio-IT World. Retrieved 4 November 2016.
  5. ^ Peterson, MC; Riggs, MM (March 2015). "FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?". CPT: Pharmacometrics & Systems Pharmacology. 4 (3): 189–192. doi:10.1002/psp4.20. PMC 4394612. PMID 26225239.
  6. ^ Azer, Karim (2021). "History and Future Perspectives on the Discipline of Quantitative Systems Pharmacology Modeling and Its Applications". Frontiers in Pharmacology. 12. doi:10.3389/fphys.2021.637999. PMC 8027332. PMID 33841175.
  7. ^ "Model-Informed Drug Development Paired Meeting Program". fda.gov. FDA. Retrieved 17 July 2023.

External links[edit]